Fosamprenavir calcium cas: 226700-81-8

CAS NO: 226700-81-8
Fosamprenavir calcium
Description Review
Description

osamprenavir calcium (CAS: 226700-81-8) is a medication used to treat HIV infection. It is sold under the brand name Lexiva, and it was approved by the United States Food and Drug Administration (FDA) in 2003. Fosamprenavir is a prescription drug that belongs to a class of medications called protease inhibitors. In this article, we will discuss the chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion of fosamprenavir.

Chemical name:

The chemical name of fosamprenavir calcium is [(1S,2R)-3-[(4-aminophenyl)sulfonylamino]-2-hydroxy-1-(phenylmethyl)propyl] carbamate calcium salt (1:1).

Molecular formula:

The molecular formula of fosamprenavir calcium is C25H35CaN3O9S.

Formula weight:

The formula weight of fosamprenavir calcium is 635.7 g/mol.

CAS No:

The CAS number of fosamprenavir calcium is 226700-81-8.

Top ten keywords from Google and Synonyms:

  1. HIV/AIDS
  2. Protease inhibitor
  3. Antiretroviral therapy
  4. Lexiva
  5. Fosamprenavir calcium hydrate
  6. Retroviral medication
  7. AIDS medication
  8. Prezista
  9. Antiviral drug
  10. Boosted PI

Health benefits of this product:

The primary health benefit of fosamprenavir is its ability to treat HIV infection. The medication works by inhibiting the activity of the HIV protease enzyme, which is necessary for the virus to replicate. By inhibiting protease, fosamprenavir can slow the progression of HIV infection and reduce the risk of developing AIDS.

Potential effects:

Fosamprenavir has several potential effects on the body. The medication works by inhibiting the activity of the HIV protease enzyme, which prevents the virus from replicating and infecting new cells. Additionally, fosamprenavir may also have some immunomodulatory effects, which can help improve the function of the immune system.

Product mechanism:

Fosamprenavir works by inhibiting the activity of the HIV protease enzyme. This enzyme is necessary for the virus to replicate and infect new cells. By inhibiting protease, fosamprenavir can slow the progression of HIV infection and reduce the risk of developing AIDS. Fosamprenavir is often used in combination with other antiretroviral medications to suppress the virus and prevent the development of drug resistance.

Safety:

Fosamprenavir is generally considered safe when used as directed. Like all medications, it can cause side effects, but serious adverse effects are rare. Some concerns have been raised about the potential for fosamprenavir to interact with other medications or cause liver damage. However, these risks are typically low when the medication is used appropriately and monitored closely by a healthcare provider.

Side effects:

The most common side effects of fosamprenavir include diarrhea, nausea, vomiting, headache, and fatigue. Less commonly reported side effects include abdominal pain, rash, and fever. Rarely, fosamprenavir may cause serious side effects, including liver damage, allergic reactions, and changes in blood sugar or cholesterol levels. People taking fosamprenavir should talk to their healthcare provider if they experience any unusual symptoms.

Dosing information:

The recommended dose of fosamprenavir is 1400 mg twice daily, taken with food. For people who are unable to tolerate this dose, lower doses may be prescribed. Fosamprenavir is often used in combination with other antiretroviral medications to suppress the virus and prevent drug resistance.

Conclusion:

Fosamprenavir calcium is a medication used to treat HIV infection. The medication works by inhibiting the activity of the HIV protease enzyme, preventing the virus from replicating and infecting new cells. While fosamprenavir is generally considered safe, it can cause side effects, and there are some concerns about potential interactions with other medications or liver damage. People considering using fosamprenavir to treat HIV should talk to their healthcare provider to determine if it is the right choice for them

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code